The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Jr., Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009. doi:10.1038/nrdp.2015.9
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–180. doi:10.1016/S1470-2045(10)70087-5
   PubMed Web of Science ®Google Scholar
• Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 2017;117(7):913–920. doi:10.1038/bjc.2017.274
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with nsclc. J Thorac Oncol. 2010;5(5):620–630. doi:10.1097/JTO.0b013e3181d2dcd9
   PubMed Web of Science ®Google Scholar
• Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C, Cihan S. Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Lung Cancer. 2019;133:38–44. doi:10.1016/j.lungcan.2019.05.007
   PubMed Web of Science ®Google Scholar
• Morel H, Raynard B, d’Arlhac M, Hauss P-A, Lecuyer E, Oliviero G, Marty C, Gury J-P, Asselain B, Grivaux M, et al. Prediagnosis weight loss, a stronger factor than bmi, to predict survival in patients with lung cancer. Lung Cancer. 2018;126:55–63. doi:10.1016/j.lungcan.2018.07.005
   PubMed Web of Science ®Google Scholar
• Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, Jiao Y. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer. 2013;132(5):1162–1169. doi:10.1002/ijc.27719
   PubMed Web of Science ®Google Scholar
• Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, Montemurro F, Bernardo A, Risi E, Zanardi E, et al. Impact of body mass index on the clinical outcomes of patients with her2-positive metastatic breast cancer. Breast. 2018;37:142–147. doi:10.1016/j.breast.2017.11.004
   PubMed Web of Science ®Google Scholar
• Alarfi H, Salamoon M, Kadri M, Alammar M, Haykal MA, Alseoudi A, Youssef LA. The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study. BMC Res Notes. 2017;10(1):550. doi:10.1186/s13104-017-2876-2
   PubMedGoogle Scholar
• Bi H, Huang Y, Wang G, Ma L, Lu M. Impact of body mass index and pretreatment hemoglobin level on prognosis following radical cystectomy for bladder cancer in males and females. Urol Int. 2020;104(1-2):28–35. doi:10.1159/000500561
   PubMed Web of Science ®Google Scholar
• Jiang QL, Wang CF, Tian YT, Huang H, Zhang SS, Zhao DB, Ma J, Yuan W, Sun YM, Che X, et al. Body mass index does not affect the survival of pancreatic cancer patients. WJG. 2017;23(34):6287–6293. doi:10.3748/wjg.v23.i34.6287
   PubMed Web of Science ®Google Scholar
• Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X. The influence of body mass index on overall survival following surgical resection of non-small cell lung cancer. J Thorac Oncol. 2017;12(8):1280–1287. doi:10.1016/j.jtho.2017.05.010
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on eastern cooperative oncology group clinical trials. J Thorac Oncol. 2013;8(9):1121–1127. doi:10.1097/JTO.0b013e31829cf942
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Xu W, Lu L, Fares A, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz AG, et al. Body mass index (bmi), bmi change, and overall survival in patients with sclc and nsclc: a pooled analysis of the international lung cancer consortium. J Thorac Oncol. 2019;14(9):1594–1607. doi:10.1016/j.jtho.2019.05.031
   PubMed Web of Science ®Google Scholar
• Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: Influence of smoking, gender and body mass index. Carcinogenesis. 1992;13(12):2241–2247. doi:10.1093/carcin/13.12.2241
   PubMed Web of Science ®Google Scholar
• Li X, Bai Y, Wang S, Nyamathira SM, Zhang X, Zhang W, Wang T, Deng Q, He M, Zhang X, et al. Association of body mass index with chromosome damage levels and lung cancer risk among males. Sci Rep. 2015;5:9458. doi:10.1038/srep09458
   PubMed Web of Science ®Google Scholar
• Cui G, Staron MM, Gray SM, Ho PC, Amezquita RA, Wu J, Kaech SM. Il-7-induced glycerol transport and tag synthesis promotes memory cd8+ t cell longevity. Cell. 2015;161(4):750–761. doi:10.1016/j.cell.2015.03.021
   PubMed Web of Science ®Google Scholar
• Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ. Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res. 2010;2:27–38. doi:10.2147/cmar.s7101
   PubMedGoogle Scholar
• Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–799. doi:10.1016/j.clnu.2008.06.013
   PubMed Web of Science ®Google Scholar
• Kawai H, Ota H. Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg. 2012;36(12):2853–2857. doi:10.1007/s00268-012-1766-y
   PubMed Web of Science ®Google Scholar
• Tomita M, Ayabe T, Nakamura K. Low body mass index is an independent predictive factor after surgical resection in patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2017;18(12):3353–3356.
   PubMedGoogle Scholar
• Sepesi B, Correa AM, Dmitrovsky E, Liu X. Reply to “influence of body mass index on overall survival following surgical resection of non-small cell lung cancer: Methodological issues”. J Thorac Oncol. 2017;12(9):e150–e151. doi:10.1016/j.jtho.2017.07.003
   PubMedGoogle Scholar
• Attaran S, McShane J, Whittle I, Poullis M, Shackcloth M. A propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index. Eur J Cardiothorac Surg. 2012;42(4):653–658. doi:10.1093/ejcts/ezs135
   PubMed Web of Science ®Google Scholar
• Takada K, Shimokawa M, Akamine T, Ono Y, Haro A, Osoegawa A, Tagawa T, Mori M. Association of low body mass index with poor clinical outcomes after resection of non-small cell lung cancer. Anticancer Res. 2019;39(4):1987–1996. doi:10.21873/anticanres.13309
   PubMed Web of Science ®Google Scholar
• Henley SJ, Flanders WD, Manatunga A, Thun MJ. Leanness and lung cancer risk: Fact or artifact?. Epidemiology. 2002;13(3):268–276. doi:10.1097/00001648-200205000-00006
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the plco trial. Expert Rev Respir Med. 2019;13(10):1029–1035. doi:10.1080/17476348.2019.1656532
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, et al. A multicenter study of body mass index in cancer patients treated with anti-pd-1/pd-l1 immune checkpoint inhibitors: When overweight becomes favorable. J Immunother Cancer. 2019;7(1):57.
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322. doi:10.1016/S1470-2045(18)30078-0
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with pd-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019;9(1):2447: doi:10.1038/s41598-019-39120-6
   PubMed Web of Science ®Google Scholar
• Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 2020;6(4):512. doi:10.1001/jamaoncol.2019.5241
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Suzuki K, Imashimizu K, Banno T, Takamochi K, Oh S. Body mass index as a prognostic factor in resected lung cancer: obesity or underweight, which is the risk factor?. Thorac Cardiovasc Surg. 2015;63(07):551–557. doi:10.1055/s-0035-1554964
   PubMedGoogle Scholar
• Nam MW, Kim JM, Cheong JH, Ryu JI, Han MH. Paradoxical relationship between body mass index and bone mineral density in patients with non-small cell lung cancer with brain metastasis. PLoS One. 2019;14(6):e0218825. doi:10.1371/journal.pone.0218825
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczęsna A, Fidias P, et al. Randomized, multinational, phase iii study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The tax 326 study group. JCO. 2003;21(16):3016–3024. doi:10.1200/JCO.2003.12.046
   PubMed Web of Science ®Google Scholar
• Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, et al. Phase iii trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003;98(3):542–553. doi:10.1002/cncr.11535
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase iii study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in japan. Ann Oncol. 2007;18(2):317–323. doi:10.1093/annonc/mdl377
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Group CM-a, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–857. doi:10.1093/jnci/djk196
   PubMed Web of Science ®Google Scholar